← Back to Screener
Relay Therapeutics, Inc. Common Stock (RLAY)
Price$16.40
Favorite Metrics
Price vs S&P 500 (26W)149.10%
Price vs S&P 500 (4W)59.63%
Market Capitalization$3.00B
All Metrics
Book Value / Share (Quarterly)$3.26
P/TBV (Annual)2.59x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)123.25%
Cash Flow / Share (Quarterly)$-1.36
Price vs S&P 500 (YTD)93.97%
Net Profit Margin (TTM)-1317.60%
EPS (TTM)$-1.61
10-Day Avg Trading Volume3.87M
EPS Excl Extra (TTM)$-1.61
Revenue Growth (5Y)-28.58%
EPS (Annual)$-1.61
ROI (Annual)-48.76%
Net Profit Margin (5Y Avg)-7914.86%
Cash / Share (Quarterly)$3.19
ROA (Last FY)-44.50%
Revenue Growth TTM (YoY)53.45%
EBITD / Share (TTM)$-1.75
ROE (5Y Avg)-41.75%
Operating Margin (TTM)-1447.94%
Cash Flow / Share (Annual)$-1.36
P/B Ratio5.28x
P/B Ratio (Quarterly)2.59x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)189.60x
ROA (TTM)-39.22%
EPS Incl Extra (Annual)$-1.61
Current Ratio (Annual)22.61x
Quick Ratio (Quarterly)21.91x
3-Month Avg Trading Volume2.67M
52-Week Price Return542.15%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.26
P/S Ratio (Annual)195.08x
Asset Turnover (Annual)0.02x
52-Week High$17.32
Operating Margin (5Y Avg)-8175.41%
EPS Excl Extra (Annual)$-1.61
CapEx CAGR (5Y)-26.64%
26-Week Price Return157.85%
Quick Ratio (Annual)21.91x
13-Week Price Return107.68%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)22.61x
Enterprise Value$2,911.427
Revenue / Share Growth (5Y)-37.24%
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)-17.42%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1800.58%
Cash / Share (Annual)$3.19
3-Month Return Std Dev74.56%
Net Income / Employee (TTM)$-1
ROE (Last FY)-48.76%
EPS Basic Excl Extra (Annual)$-1.61
Receivables Turnover (TTM)19.65x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.61
Receivables Turnover (Annual)9.83x
ROI (TTM)-43.17%
P/S Ratio (TTM)195.07x
Pretax Margin (5Y Avg)-7914.86%
Revenue / Share (Annual)$0.09
Tangible BV / Share (Annual)$3.26
Price vs S&P 500 (52W)507.05%
Year-to-Date Return98.11%
5-Day Price Return9.83%
EPS Normalized (Annual)$-1.61
ROA (5Y Avg)-37.25%
Net Profit Margin (Annual)-1800.58%
Month-to-Date Return68.44%
Cash Flow / Share (TTM)$-2.64
EBITD / Share (Annual)$-1.75
Operating Margin (Annual)-1971.59%
ROI (5Y Avg)-41.75%
EPS Basic Excl Extra (TTM)$-1.61
P/TBV (Quarterly)2.59x
P/B Ratio (Annual)2.59x
Pretax Margin (TTM)-1317.60%
Book Value / Share (Annual)$3.26
Price vs S&P 500 (13W)104.82%
Beta1.98x
Revenue / Share (TTM)$0.09
ROE (TTM)-43.17%
52-Week Low$2.53
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.28
4.39
4.39
4.39
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RLAYRelay Therapeutics, Inc. Common Stock | 195.07x | 53.45% | — | — | $16.40 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Relay Therapeutics is a clinical-stage precision medicine company using its proprietary Dynamo platform—which combines computational and experimental approaches—to target difficult drug-protein interactions in precision oncology and genetic disease. The company is advancing a pipeline of candidates including RLY-8186, RLY-2608, and RLY-4008.